An alternative approach, based on cytosol-penetrating antibodies via heparan sulfate proteoglycan binding, relied on reducing HSPG-binding affinity in combination with the coupling of TAA-specific cyclic peptides, targeting tumor-associated integrin αvβ3 and/or αvβ5 or tumor-associated epithelial cell adhesion molecule (EpCAM).13 The gene discussed is CD44; the disease is neoplasm.